Razi Cov Pars (Persian: رازی کوو پارس) is a COVID-19 vaccine developed by the Iranian Razi Vaccine and Serum Research Institute Razi Cov Pars is a covid-19... 11 KB (813 words) - 22:10, 27 March 2024 |
Travel-only Hungary Malaysia New Zealand Turkey Razi Cov Pars is a protein subunit vaccine developed by Razi Vaccine and Serum Research Institute. Full (0)... 318 KB (19,351 words) - 20:33, 14 March 2024 |
antigens and diagnostic kits for medical and veterinary labs. 2021: Razi Cov Pars: a COVID-19 vaccine The facility was used as a Soviet military base... 5 KB (401 words) - 19:17, 23 January 2024 |
COVID-19 vaccine (redirect from Sars cov 2 vaccine) acquired immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID‑19). Prior to the... 191 KB (21,884 words) - 08:58, 18 March 2024 |
have been developed with the onset of the COVID-19 pandemic. inCOVACC, Razi Cov Pars, Sputnik, and Convidicia are nasal COVID-19 vaccines that were developed... 29 KB (3,397 words) - 17:20, 29 September 2023 |
Corbevax, COVAX-19, EpiVacCorona, IndoVac, MVC-COV1901, Noora, Novavax, Razi Cov Pars, Sanofi–GSK, Sinopharm CNBG, Skycovione, Soberana 02, Soberana Plus... 98 KB (20,593 words) - 02:58, 8 March 2024 |
authorization (COVIran Barekat, Pasteurcovac, FAKHRAVAC, COVAX-19 and Razi Cov Pars). The new drugs launched in Iran for the treatment of MS include an... 37 KB (3,558 words) - 01:11, 25 January 2024 |
with an Australian company, received EUA in Iran on 6 October 2021. Razi Cov Pars: received EUA on 31 October 2021. Other candidate vaccines that have... 240 KB (18,865 words) - 08:40, 14 March 2024 |